COPD (Chronic Obstructive Pulmonary Disease) is an inflammatory lung disease that causes minor airway obstruction and tissue damage in the lung alveoli.
Inhaled bronchodilators and inhaled corticosteroids (ICS) are the mainstays of current COPD therapy (inhaled Corticosteroids). The management of inflammation is the most important aspect of COPD treatment. However, COPD inflammation is partly immune to steroid treatment. Since ICS may only temporarily reduce inflammation in COPD, it is necessary to develop new anti-inflammatory therapies or drugs.
Plant Artemisia Argyi, also known as moxa. Orthodox Chinese herbalists have used its leaves to treat a variety of ailments. To treat different diseases, dried moxa fluff is made into a stick and used to heat specific points on the patient’s face. Moxibustion is the name for this treatment.
The mechanism of moxibustion, according to the author’s experiments, is that the smoke or tar of the burning moxa has a special anti-inflammatory property that can treat and cure Steroid resistant chronic non-specific inflammation.
To treat 25 COPD patients, the author develops a novel anti-inflammatory treatment involving the inhalation of moxa smoke. After 1 to 2 months of therapy, 22 of 25 patients were symptom-free and remained symptom-free even after the treatment was stopped.
Author (s) Details
Medi7 Clinic Bentleigh, Australia.
View Book :- https://stm.bookpi.org/CDHR-V7/article/view/915